Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.

Breaking & Recent News argenx SE ARGX

argenx SE is an immunology company. It is engaged in the business of developing a pipeline of differentiated antibody-based therapies for the treatment of severe autoimmune diseases and cancer. The group has partnered with academic researchers through its Immunology Innovation Program (IIP) and aims to translate immunology breakthroughs into a portfolio of novel antibody-based medicines. argenx developed and is commercializing the neonatal Fc receptor (FcRn) blocker in the U.S., Japan, and the EU. Its product pipeline includes product candidates such as ARGX-117, ARGX-118, ARGX-115, ARGX-116, and others.


Recent & Breaking News (NDAQ:ARGX)

argenx to Present at 2021 Wedbush PacGrow Virtual Healthcare Conference

GlobeNewswire August 4, 2021

argenx Reports Half Year 2021 Financial Results and Provides Second Quarter Business Update

GlobeNewswire July 29, 2021

argenx to Report Half Year 2021 Financial Results and Second Quarter Business Update on July 29, 2021

GlobeNewswire July 22, 2021

argenx to Host Virtual R&D Day on July 20, 2021

GlobeNewswire July 14, 2021

argenx announces publication of Phase 3 ADAPT trial results of efgartigimod for the treatment of generalized myasthenia gravis in The Lancet Neurology

GlobeNewswire June 16, 2021

argenx to regain global rights to cusatuzumab

GlobeNewswire June 7, 2021

argenx Appoints Karl Gubitz as Chief Financial Officer

GlobeNewswire June 1, 2021

argenx to Present at Upcoming Investor Conferences

GlobeNewswire June 1, 2021

argenx Reports First Quarter 2021 Financial Results and Provides Business Update

GlobeNewswire May 14, 2021

argenx announces results of Annual General Meeting of Shareholders

GlobeNewswire May 11, 2021

argenx to Report First Quarter 2021 Financial Results and Business Update on May 14, 2021

GlobeNewswire May 7, 2021

argenx Management to Present at Upcoming Virtual Investor Conferences

GlobeNewswire April 28, 2021

argenx announces Annual General Meeting of Shareholders on May 11, 2021

GlobeNewswire March 30, 2021

argenx Reports Full Year 2020 Financial Results and Provides Fourth Quarter Business Update

GlobeNewswire March 4, 2021

argenx Announces FDA Acceptance of BLA Filing for Efgartigimod for the Treatment of Generalized Myasthenia Gravis

GlobeNewswire March 2, 2021

argenx to Report Full Year 2020 Financial Results and Fourth Quarter Business Update on March 4, 2021

GlobeNewswire February 25, 2021

argenx announces closing of global offering

GlobeNewswire February 5, 2021

argenx announces full exercise of underwriters' option to purchase additional ADSs

GlobeNewswire February 4, 2021

argenx raises $1.0 billion in gross proceeds in a global offering

GlobeNewswire February 2, 2021

argenx Issues Statement Concerning Efgartigimod

GlobeNewswire February 2, 2021